Rate of Detecting Positive Markers of Covid-19 in Persons with Various Vaccination Anamnesis
P. V. Tsygankov,
A. B. Alnikin,
I. V. Kvashe,
S. V. Shlyk,
G. G. Kharseeva,
O. A. Ryabtseva,
I. V. Tarabanova https://doi.org/10.31631/2073-3046-2021-20-3-4-7
Abstract
Relevance. Currently, the incidence of COVID-19 is growing in many countries of the world, including Russia. There are suggestions about a likely protective role against the new coronavirus infection of widely used traditional vaccines against respiratory infections (influenza, tuberculosis, pneumococcal infection). Those vaccinated with these vaccines are less likely to report deaths and severe forms of COVID-19 diseases in vulnerable populations.
The aim is to determine the frequency of detection of positive markers of a new coronavirus infection in individuals with different vaccination histories.
Materials and methods. We examined 313 employees of an educational institution with various vaccination histories at the age of 20–54 years from May to September 2020. The determination of SARS-CoV-2 RNA and specific IgM and IgG antibodies to the virus nucleocapsid was carried out.
Results. Positive markers for SARS-CoV-2 (PCR and / or ELISA) were found in 51 (16.3%) people. All examined patients had no signs of acute respiratory viral infections. Among people with positive markers of coronavirus infection (PCR and / or ELISA), the number of people vaccinated against diphtheria, tetanus, measles and hepatitis B (HBV) was 13.7–17.6% of those examined. Among those with negative PCR results, the number of people vaccinated against these infections was higher (p ≤ 0.05) and amounted to 51.0–56.6%. Similar results were found in the determination of specific IgM and IgG.
Conclusion. Positive markers of a new coronavirus infection were found much less frequently in persons who had a history of vaccination with ADS-M-toxoid, measles and hepatitis B vaccines.
About the Authors
P. V. Tsygankov
Rostov State Medical University
Russian Federation
Russian Federation
Petr V. Tsygankov – Vice rector for clinical work, head of clinic, assistant of the surgical diseases chair № 2.
29, Nakhichevan lane, Rostov-on-Don, 344022
A. B. Alnikin
Rostov State Medical University
Russian Federation
Russian Federation
Alexander B. Alnikin – Cand. Sci. (Med.), assistant of the Department of surgical diseases No. 2, chief physician of the clinic.
29, Nakhichevan lane, Rostov-on-Don, 344022
I. V. Kvashe
Rostov State Medical University
Russian Federation
Russian Federation
Irina V. Kvashе –epidemiologist of the clinic.
29, Nakhichevan lane, Rostov-on-Don, 344022
S. V. Shlyk
Rostov State Medical University
Russian Federation
Russian Federation
Sergey V. Shlyk – Dr. Sci. (Med.), Professor, Rector of the Department of Therapy.
29, Nakhichevan lane, Rostov-on-Don, 344022
G. G. Kharseeva
Rostov State Medical University
Russian Federation
Russian Federation
Galina G. Kharseeva – Dr. Sci. (Med.), Professor, Head of the Department of Microbiology and Virology №2.
29, Nakhichevan lane, Rostov-on-Don, 344022
O. A. Ryabtseva
Rostov State Medical University
Russian Federation
Russian Federation
Olga A. Ryabtseva – Cand. Sci. (Med.), otolaryngologist, doctor of the highest category.
29, Nakhichevan lane, Rostov-on-Don, 344022
I. V. Tarabanova
Rostov State Medical University
Russian Federation
Russian Federation
Irene V. Tarabanova – senior nurse of the medical center; nurse of the consultative and polyclinic Department; College teacher.
29, Nakhichevan lane, Rostov-on-Don, 344022
References
1. Avdeev SN, Adamyan LV, Alekseeva EI, et al. Prevention, diagnosis and treatment of new coronavirus infection (COVID-2019). Vremennye metodicheskie rekomendacii. Version 7 (06.03.2020). Moscow, 2020 (In Russ.).
2. Briko NI, Kagramanyan IN, Nikiforov VV, et al. Pandemic COVID-19. Measures to combat its spread in the Russian Federation. Epidemiology and Vaccinal Prevention. 2020;19(2):4–12 (In Russ.).
3. Nikiforov VV, Suranova TG, Mironov AYu, et al. Novel coronavirus infection (COVID-19): etiology, epidemiology, clinical presentation, diagnosis, treatment and prevention. Uchebno-metodicheskie posobie. Moscow; 2020 (In Russ.).
4. Kostinov MP. Immunopathogenic properties of SARS-COV-2 as a basis for the choice of pathogenetic therapy. Immunology. 2020; Т. 41 (1): 83–91 (In Russ.).
5. Kostinov MP. Fundamentals of immunorehabilitation for new coronavirus infection (COVID-19). Posobie dlja vrachej. Moscow: Gruppa MDV, 2020 (In Russ.).
6. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061–1069. doi: 10.1001/jama. 2020.1585.
7. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395 (10223): 507–513. doi: 10.1016/S0140-6736(20)30211-7.
8. Kostinov MP, Svitich OA, Markelova EV. Potential COVID-19 immunization in high-risk groups. Vremennoe posobie dlja vrachej. Moscow; 2020 (In Russ.).
9. Blok BA, Arts RJW, van Crevel R, et al. Differential effects of BCG vaccine on immune responses induced by Vi polysaccharide typhoid fever vaccination: an explorative randomized trial. Eur J Clin Microb Infect Dis. 2020; 39:1177–1184. doi.org/10.1007/s10096-020-03813-y.
10. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1,590 patients with Covid-19 in China: A nationwide analysis. Eur Respir J. 2020; 55(5): 2000547. doi: 10.1183/13993003.00547-2020.
11. Thevarajan I, Nguyen THO., Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature Medicine. Nature Research. 2020; 26: 453–455. doi: 10.1038/s41591-020-0819-2.
12. Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004; 18 (4): 761–776. doi: 10.1016/j. idc.2004.08.003.
13. De Blasio A, Chioni L, Adorni G. Differential Diagnosis of Types of Pneumonia in the Elderly. In: Vargas N., Esquinas A. (eds.). Covid19 Airway Management and Ventilation Strategy for Critically Ill Older Patients. Springer, Cham; 2020. Available at: http://link.springer.com/10.1007/978-3-030-55621-1_5.
14. Mimura K, Kimura S, Kajiwara C, et al. Pneumococcal conjugate vaccine modulates macrophage-mediated innate immunity in pneumonia caused by Streptococcus pneumoniae following influenza. Microbes Infect. 2020; 22(8): 312–321. doi: 10.1016/j. micinf.2019.12.005.
15. Kostinov MP, Kostinov AM. Twenty years of clinical experience in the use of pneumococcal polysaccharide vaccine in Russia in children with health disorders (information material for preparing a lecture). Infectious Diseases: News, Opinions, Education. 2019; 8(2): 118–128. (In Russ.) doi: 10.24411/2305-3496-2019-12015.
16. Kostinov MP, Kostinov AM, Pakhomov DV, et al. Efficiency of pneumococcal vaccine in immunocompetent patients. Journal of Microbiology, Epidemiology and Immunology. 2019; (5): 72–83. (In Russ.) doi: 10.36233/0372-9311-2019-5-72-83.
Review
For citations:
Tsygankov P.V., Alnikin A.B., Kvashe I.V., Shlyk S.V., Kharseeva G.G., Ryabtseva O.A., Tarabanova I.V. Rate of Detecting Positive Markers of Covid-19 in Persons with Various Vaccination Anamnesis. Epidemiology and Vaccinal Prevention. 2021;20(3):4-7. (In Russ.) https://doi.org/10.31631/2073-3046-2021-20-3-4-7
Views:
841
Email this article 